PKR-IN-C16
(Synonyms: C16,GW 506033X,Protein Kinase RNA-activated) 目录号 : GC17925
PKR-IN-C16是一种靶向ATP结合位点的小分子化合物，能够抑制RNA依赖性蛋白激酶（PKR）的自磷酸化，IC50值为0.21±0.04μM。
Cas No.:608512-97-6
Sample solution is provided at 25 µL, 10mM.
PKR-IN-C16 is an ATP-binding site-directed small molecule that inhibits RNA-dependent protein kinase (PKR) autophosphorylation, with an IC50 value of 0.21±0.04μM[1]. PKR-IN-C16 has been widely used in the research of neuroprotection for brain injuries, as well as in the preparation of new mRNA vaccine formulations to enhance the translation and expression of mRNA[2-3].
In vitro, PKR-IN-C16 treatment at 0.5μM for 24 hours can significantly reduce the phosphorylation of eIF2α in DYT-PRKRA lymphoblasts and inhibit cell apoptosis[4]. PKR-IN-C16 treatment (6μM; 2.5h) significantly stimulated the integrated stress response (ISR) in HeLa cells, accompanied by the enhanced expression of PERK and GCN2 proteins[5]. Treatment with 2μM PKR-IN-C16 for 7 days significantly inhibited the proliferation of HCT116 cells and reduced cell division[6].
In vivo, PKR-IN-C16 treatment (300μg/kg/day; i.p.) reduced the tumor growth rate, decreased tumor volume, inhibited CD31 expression, and suppressed angiogenesis in the mouse xenograft tumor model[7]. A day after injecting PKR-IN-C16 into the abdominal cavity at a dose of 100μg/kg, the volume of the infarct after ischemia and the apoptosis rate were notably decreased in the hypoxic-ischemic rat model[8]. Intraperitoneal injection of 600μg/kg dose of PKR-IN-C16 within 24 hours in the model of toxic neuroinflammation in rats can prevent PKR-induced neuronal loss and reduce the inflammatory response[9].
References:
[1] Jammi N V, Whitby L R, Beal P A. Small molecule inhibitors of the RNA-dependent protein kinase[J]. Biochemical and biophysical research communications, 2003, 308(1): 50-57.
[2] Couturier J, Paccalin M, Lafay-Chebassier C, et al. Pharmacological inhibition of PKR in APPswePS1dE9 mice transiently prevents inflammation at 12 months of age but increases Aβ42 levels in the late stages of the Alzheimer’s disease[J]. Current Alzheimer research, 2012, 9(3): 344-360.
[3] Zhang W, Liu Y, Chin J M, et al. Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination[J]. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163: 179-187.
[4] Frederick K, Patel R C. Luteolin protects DYT-PRKRA cells from apoptosis by suppressing PKR activation[J]. Frontiers in Pharmacology, 2023, 14: 1118725.
[5] Szaruga M, Janssen D A, de Miguel C, et al. Activation of the integrated stress response by inhibitors of its kinases[J]. Nature communications, 2023, 14(1): 5535.
[6] Hashimoto Y, Tokumoto Y, Watanabe T, et al. C16, a PKR inhibitor, suppresses cell proliferation by regulating the cell cycle via p21 in colorectal cancer[J]. Scientific reports, 2024, 14(1): 9029.
[7] Watanabe T, Ninomiya H, Saitou T, et al. Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo[J]. Scientific reports, 2020, 10(1): 5133.
[8] Xiao J, Tan Y, Li Y, et al. The specific protein kinase R (PKR) inhibitor C16 protects neonatal hypoxia-ischemia brain damages by inhibiting neuroinflammation in a neonatal rat model[J]. Medical science monitor: international medical journal of experimental and clinical research, 2016, 22: 5074.
[9] Tronel C, Page G, Bodard S, et al. The specific PKR inhibitor C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component[J]. Neurochemistry international, 2014, 64: 73-83.
PKR-IN-C16是一种靶向ATP结合位点的小分子化合物，能够抑制RNA依赖性蛋白激酶（PKR）的自磷酸化，IC50值为0.21±0.04μM[1]。PKR-IN-C16已广泛应用于脑损伤神经保护研究，以及新型mRNA疫苗制剂的制备以提高mRNA的翻译和表达水平[2-3]。
在体外，0.5μM浓度的PKR-IN-C16处理24小时可显著降低DYT-PRKRA淋巴母细胞中eIF2α的磷酸化水平，并抑制细胞凋亡[4]。6μM浓度的PKR-IN-C16处理2.5小时能显著激活HeLa细胞的整合应激反应（ISR），同时增强PERK和GCN2蛋白的表达[5]。2μM浓度的PKR-IN-C16处理7天可显著抑制HCT116细胞的增殖并减少细胞分裂[6]。
在体内，腹腔注射300μg/kg/day剂量的PKR-IN-C16可降低小鼠异种移植瘤模型中的肿瘤生长速率、缩小肿瘤体积、抑制CD31表达并减少血管生成[7]。在缺氧缺血大鼠模型中，腹腔注射100μg/kg剂量的PKR-IN-C16可在一天后显著减少缺血后的梗死体积并降低细胞凋亡率[8]。在大鼠毒性神经炎症模型中，24小时内腹腔注射600μg/kg剂量的PKR-IN-C16能预防PKR介导的神经元损失并减轻炎症反应[9]。
| Cell experiment [1]: | |
Cell lines | HCT116 cells |
Preparation Method | HCT116 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin. The cells were cultured at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. The medium was replaced three times per week. Cell viability in vitro was determined by MTS assay. The HCT116 cells treated with various concentrations (0, 0.1, 0.5, 1 and 2μM) of PKR-IN-C16 were seeded into 96-well plates at a density of 2 ×103 cells per well. The entire experiment lasted for 3 days. At each time point, the cells were incubated with MTS reagent and then further incubated for 120min. The absorbance was measured at 450nm. The cells treated with DMSO were used as the controls. The wells were imaged by a microscope. |
Reaction Conditions | 0, 0.1, 0.5, 1 and 2μM; 3 days |
Applications | PKR-IN-C16 inhibited the proliferation of HCT116 cells in vitro in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | BALB/c-nu/nu mice |
Preparation Method | For tumor xenograft analysis, Huh7 cells in the logarithmic phase in vitro were trypsinized, collected, washed, and resuspended in Dulbecco’s modified Eagle’s medium with matrix gel for tumor implantation. Female 5-week-old BALB/c-nu/nu mice were used. Subsequently, 3×106 Huh7 cells were injected subcutaneously into the right flank of nude mice. After successful implantation (about 10mm in diameter), the mice were randomized into two groups: control (n=6) and PKR-IN-C16 injection (n=6). The PKR-IN-C16 group was injected i.p. every day for 4 weeks with the PKR-IN-C16 (300μg/kg), and the control group was injected i.p. with phosphate-buffered saline. For tumor growth analysis, the tumor size was measured every day using a sliding caliper, and the tumor volume was calculated as (longest diameter) × (shortest diameter)2/2. Four weeks after transplantation, the mice were sacrificed using CO2, and the xenograft tumors were collected for immunohistochemical staining. |
Dosage form | 300μg/kg/day for 4 weeks; i.p. |
Applications | PKR-IN-C16 treatment led to a slow growth rate of tumors in mice, a reduction in tumor volume, decreased expression of CD31, and inhibition of angiogenesis. |
References: | |
| Cas No. | 608512-97-6 | SDF | |
| 别名 | C16,GW 506033X,Protein Kinase RNA-activated | ||
| 化学名 | 6,8-dihydro-8-(1H-imidazol-5-ylmethylene)-7H-pyrrolo[2,3-g]benzothiazol-7-one | ||
| Canonical SMILES | O=C1NC2=CC=C3C(SC=N3)=C2/C1=C/C4=CNC=N4 | ||
| 分子式 | C13H8N4OS | 分子量 | 268.3 |
| 溶解度 | ≤2.5mg/ml in DMSO;0.5mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7272 mL | 18.6359 mL | 37.2717 mL |
| 5 mM | 0.7454 mL | 3.7272 mL | 7.4543 mL |
| 10 mM | 0.3727 mL | 1.8636 mL | 3.7272 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
